1799 Stock Overview
Easywell Biomedicals, Inc. develops, manufactures, and sells active pharmaceutical ingredients and over-the-counter drug products in the United States and Asia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Easywell Biomedicals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$67.70 |
| 52 Week High | NT$71.40 |
| 52 Week Low | NT$19.10 |
| Beta | 0.71 |
| 1 Month Change | -3.01% |
| 3 Month Change | 70.96% |
| 1 Year Change | 253.52% |
| 3 Year Change | 166.99% |
| 5 Year Change | 303.32% |
| Change since IPO | 50.43% |
Recent News & Updates
Shareholder Returns
| 1799 | TW Medical Equipment | TW Market | |
|---|---|---|---|
| 7D | 1.0% | 1.0% | -1.6% |
| 1Y | 253.5% | 5.3% | 25.9% |
Return vs Industry: 1799 exceeded the TW Medical Equipment industry which returned 5.3% over the past year.
Return vs Market: 1799 exceeded the TW Market which returned 25.9% over the past year.
Price Volatility
| 1799 volatility | |
|---|---|
| 1799 Average Weekly Movement | 9.5% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.6% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 1799's share price has been volatile over the past 3 months.
Volatility Over Time: 1799's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | James Lee | www.easywellbio.com |
Easywell Biomedicals, Inc. develops, manufactures, and sells active pharmaceutical ingredients and over-the-counter drug products in the United States and Asia. It develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for treatment of breast cancer in PMS women; TLX-007 and TLX-004, an anti-depressant; TLX-008 for prevention of pneumocystis pneumonia; TLX-012 for treatment of epilepsy; TLX-017 for treatment of chronic angina; and TLX-011 for treatment of inflammatory lesions of rosacea. The company also develops TWB-201 for Parkinson patch; TLX-501, an urinary medicine; and TLX-502, a pneumonia medicine.
Easywell Biomedicals, Inc. Fundamentals Summary
| 1799 fundamental statistics | |
|---|---|
| Market cap | NT$8.25b |
| Earnings (TTM) | -NT$144.82m |
| Revenue (TTM) | NT$271.63m |
30.4x
P/S Ratio-57.0x
P/E RatioIs 1799 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1799 income statement (TTM) | |
|---|---|
| Revenue | NT$271.63m |
| Cost of Revenue | NT$100.91m |
| Gross Profit | NT$170.72m |
| Other Expenses | NT$315.54m |
| Earnings | -NT$144.82m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.19 |
| Gross Margin | 62.85% |
| Net Profit Margin | -53.31% |
| Debt/Equity Ratio | 6.9% |
How did 1799 perform over the long term?
See historical performance and comparison